TY - JOUR
T1 - Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma
AU - Murakami, Tetsushi
AU - Tanaka, Nobuyuki
AU - Takamatsu, Kimiharu
AU - Hakozaki, Kyohei
AU - Fukumoto, Keishiro
AU - Masuda, Tsukasa
AU - Mikami, Shuji
AU - Shinojima, Toshiaki
AU - Kakimi, Kazuhiro
AU - Tsunoda, Tatsuhiko
AU - Sawada, Kazuaki
AU - Imamura, Takeshi
AU - Mizuno, Ryuichi
AU - Oya, Mototsugu
N1 - Funding Information:
This study was supported by the Grant-in-Aid for Scientific Research (KAKENHI 19K18621 to T.M.; 18H04906, 18K19482, and 19H03792 to N.T.; 18K09150 to T.S.; 18H02939 to M.O.), the Takeda Science Foundation (N.T.), the Kobayashi Foundation for Cancer Research (N.T.), the SGH Foundation for Cancer Research (N.T.), and the Keio Gijuku Academic Development Funds (N.T.). The authors thank JKiC (JSR-Keio University Medical and Chemical Innovation Center) for special assistance to the multiplexed fluorescence imaging system.
Funding Information:
This study was supported by the Grant-in-Aid for Scientific Research (KAKENHI 19K18621 to T.M.; 18H04906, 18K19482, and 19H03792 to N.T.; 18K09150 to T.S.; 18H02939 to M.O.), the Takeda Science Foundation (N.T.), the Kobayashi Foundation for Cancer Research (N.T.), the SGH Foundation for Cancer Research (N.T.), and the Keio Gijuku Academic Development Funds (N.T.). The authors thank JKiC (JSR-Keio University Medical and Chemical Innovation Center) for special assistance to the multiplexed fluorescence imaging system.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2021/10
Y1 - 2021/10
N2 - Despite the high sensitivity of renal cell carcinoma (RCC) to immunotherapy, RCC has been recognized as an unusual disease in which CD8+ T-cell infiltration into the tumor beds is related to a poor prognosis. To approach the inner landscape of immunobiology of RCC, we performed multiplexed seven-color immunohistochemistry (CD8, CD39, PD-1, Foxp3, PD-L1, and pan-cytokeratin AE1/AE3 with DAPI), which revealed the automated single-cell counts and calculations of individual cell-to-cell distances. In total, 186 subjects were included, in which CD39 was used as a marker for distinguishing tumor-specific (CD39+) and bystander (CD39−) T-cells. Our clear cell RCC cohort also revealed a poor prognosis if the tumor showed increased CD8+ T-cell infiltration. Intratumoral CD8+CD39+ T-cells as well as their exhausted CD8+CD39+PD-1+ T-cells in the central tumor areas enabled the subgrouping of patients according to malignancy. Analysis using specimens post-antiangiogenic treatment revealed a dramatic increase in proliferative Treg fraction Foxp3+PD-1+ cells, suggesting a potential mechanism of hyperprogressive disease after uses of anti-PD-1 antibody. Our cell-by-cell study platform provided spatial information on tumors, where bystander CD8+CD39− T-cells were dominant in the invasive margin areas. We uncovered a potential interaction between CD8+CD39+PD-1+ T-cells and Foxp3+PD-1+ Treg cells due to cell-to-cell proximity, forming a spatial niche more specialized in immunosuppression under PD-1 blockade. A paradigm shift to the immunosuppressive environment was more obvious in metastatic lesions; rather the infiltration of Foxp3+ and Foxp3+PD-1+ Treg cells was more pronounced. With this multiplexed single-cell pathology technique, we revealed further insight into the immunobiological standing of RCC.
AB - Despite the high sensitivity of renal cell carcinoma (RCC) to immunotherapy, RCC has been recognized as an unusual disease in which CD8+ T-cell infiltration into the tumor beds is related to a poor prognosis. To approach the inner landscape of immunobiology of RCC, we performed multiplexed seven-color immunohistochemistry (CD8, CD39, PD-1, Foxp3, PD-L1, and pan-cytokeratin AE1/AE3 with DAPI), which revealed the automated single-cell counts and calculations of individual cell-to-cell distances. In total, 186 subjects were included, in which CD39 was used as a marker for distinguishing tumor-specific (CD39+) and bystander (CD39−) T-cells. Our clear cell RCC cohort also revealed a poor prognosis if the tumor showed increased CD8+ T-cell infiltration. Intratumoral CD8+CD39+ T-cells as well as their exhausted CD8+CD39+PD-1+ T-cells in the central tumor areas enabled the subgrouping of patients according to malignancy. Analysis using specimens post-antiangiogenic treatment revealed a dramatic increase in proliferative Treg fraction Foxp3+PD-1+ cells, suggesting a potential mechanism of hyperprogressive disease after uses of anti-PD-1 antibody. Our cell-by-cell study platform provided spatial information on tumors, where bystander CD8+CD39− T-cells were dominant in the invasive margin areas. We uncovered a potential interaction between CD8+CD39+PD-1+ T-cells and Foxp3+PD-1+ Treg cells due to cell-to-cell proximity, forming a spatial niche more specialized in immunosuppression under PD-1 blockade. A paradigm shift to the immunosuppressive environment was more obvious in metastatic lesions; rather the infiltration of Foxp3+ and Foxp3+PD-1+ Treg cells was more pronounced. With this multiplexed single-cell pathology technique, we revealed further insight into the immunobiological standing of RCC.
KW - CD39
KW - CD8
KW - Heterogeneity
KW - Kidney
KW - PD-1
KW - Renal cell carcinoma
KW - Single cell
UR - http://www.scopus.com/inward/record.url?scp=85114404365&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114404365&partnerID=8YFLogxK
U2 - 10.1007/s00262-021-03006-2
DO - 10.1007/s00262-021-03006-2
M3 - Article
C2 - 34259900
AN - SCOPUS:85114404365
SN - 0340-7004
VL - 70
SP - 3001
EP - 3013
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
IS - 10
ER -